Aurore pharmaceuticals is an API and finished-dose manufacturer based in India. It appears in 141 regulatory filings across 9 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), PPB (KE) and UZPHARM (UZ). Its GMP standing is certified by EAEU_EEC, MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 31 May 2024 as VAI. Customs aggregates show $603K of exports covering 17 molecules to 7 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hyderabad, India | 3003937580 |
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 36 | None |
| PPB (KE) | 26 | None |
| UZPHARM (UZ) | 25 | None |
| MINSA (CR) | 18 | None |
| INVIMA (CO) | 14 | None |
| RCETH (BY) | 10 | None |
| EAEU_EEC | None | 7 |
| MFDS (Korea) | None | 2 |
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $30K | 3 |
| 2025 | Not reported | $603K | 7 |
| 2024 | Not reported | $359K | 6 |
| 2023 | Not reported | $1.6M | 10 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Aurore pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free